Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance its gene therapy pipeline. The PRV was awarded after the US Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results